Kronos calls time on CMO, CSO roles as part of C-suite shakeup

2024-01-25
FierceBiotech
高管变更
Replacing the three jettisoned C-suite roles will be four SPV positions overseeing: R&D; clinical development; corporate strategy and portfolio management; and corporate operations and legal.
Kronos Bio had already trimmed back its headcount and pipeline in the wake of a mid-stage cancer flop. Now, it’s the company’s C-suite who are heading to the exits.
Kronos Bioh has “eliminated three executive officer roles”—meaning Chief Medical Officer JcanceriMartino, M.D., Chief Scientific Officer Christopher Dinsmore, Ph.D., and Chief Operating Officer and General Counsel Barbara Kosacz will all be out of a job.
The company explained the changes were needed to ensure a “streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio’s current operating needs.”
The three executives will leave the company on Feb.16, although they will remain as strategic advisors for the business, according to a Jan. 25 pressKronos Bio
The leadership shakeup follows a headcount reduction of 19% in November in order to fund KB-0742, a CDK9 inhibitor currently in a phase 1/2 trial for solid tumors and non-Hodgkin lymphoma. A month after the layoffs, Kronos said it was discontinuing a cancer trial for lanraplenib and seeking a partner for the SYK inhibitor in the wake of a mid-stage trial flop.
“This new leadership structure is designed to streamline our operations and reflects our KB-0742 effCDK9 inhibitorCDK9to advance our pipeline, optimize our resourcesolid tumorsientlnon-Hodgkin lymphomainess objectives,” CEO Norbert Bischofberger, Ph.D., said in thecancerse.lanraplenibSYK inhibitorSYK
“I would like to thank Jorge, Chris, and Barbara for their leadership and dedication, and I wish them well in their future endeavors,” Bischofberger added. “They each built and managed strong teams, laying the groundwork for this new structure and preparing our future leaders for success.”
Replacing the three jettisoned C-suite roles will be four SPV positions overseeing R&D; clinical development; corporate strategy and portfolio management; and corporate operations and legal. Those positions are filled by Charles Lin, Ph.D., Elizabeth Olek, Rocio Martin Hoyos and Allison Frisbee, respectively.
Kronos said it expects to make savings from the changes, even after termination costs are accounted for.
Kronoss KB-0742, Kronos has a partnership with Roche’s Genentech for several undisclosed discovery programs. Inked a year ago, the Genentech partnership is crucial for Kronos, coming right after the biotech kicked a late-stage AML asset called entospletinib to the curb. The Roche unit jumped in to save the day for the struggling biotech with a $20 million upfront payment plus milestones that could top $177 million for the first program and $100 million for the first licensed product.
Kronos aKB-0742enKronosvealed a new developmentRocheidaGenentechd KB-9558. The preclinical asset is designed to modulate the IRF4 tGenentechion regulatory network—a keyKronosr in multiple myeloma.AMLAMLentospletinibRoche
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。